YmAbs is a clinical stage biopharmaceutical company focused on discovering and developing next-generation humanized, affinity matured bispecific antibodies for cancer patients. They collaborate on the development of a novel human protein tag that enhances the effectiveness of their bispecific antibodies, resulting in improved tumor binding, longer serum half-life, and increased T-cell mediated killing of tumor cells. YmAbs aims to reduce toxicities associated with current chemotherapeutics and provide potential curative therapy for patients with widespread disease. Their goal is to obtain FDA approval for multiple product candidates targeting solid tumor cancers. They have a broad and advanced product pipeline, including naxitamab and omburtamab, which target tumors expressing GD2 and B7-H3, respectively. YmAbs' mission is to become a world leader in developing antibody-based cancer products that address unmet needs in pediatric oncology, with plans to expand their capabilities to treat adults through partnerships and collaboration.